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A B S T R A C T
Atherosclerosis is the predominant underlying pathology of many types of cardiovascular disease and is one of
the leading causes of death worldwide. It is characterized by the retention of oxidized low-density lipoprotein
(ox-LDL) in lipid-rich macrophages (foam cells) in the intima of arteries. Autoantigens derived from oxLDL can
be used to vaccinate against atherosclerosis. However, a major challenge is the induction of antigen-specific
Tregs in a safe and effective way. Here we report that liposomes containing the anionic phospholipid 1,2-
distearoyl-sn-glycero-3-phosphoglycerol (DSPG) induce Tregs that are specific for the liposomes' cargo.
Mechanistically, we show a crucial role for the protein corona that forms on the liposomes in the circulation, as
uptake of DSPG-liposomes by antigen-presenting cells is mediated via complement component 1q (C1q) and
scavenger receptors (SRs). Vaccination of atherosclerotic mice on a western-type diet with DSPG-liposomes
encapsulating an LDL-derived peptide antigen significantly reduced plaque formation by 50% and stabilized the
plaques, and reduced serum cholesterol concentrations. These results indicate that DSPG-liposomes have po-
tential as a delivery system in vaccination against atherosclerosis.
1. Introduction
Atherosclerosis is a disease involving large and medium-sized ar-
teries, which affects millions of people worldwide [1]. It is initiated by
the retention of LDL in the subendothelial space of arteries, and sub-
sequent oxidation and uptake of LDL (oxLDL) by infiltrating macro-
phages leading to foam cell formation [2]. In recent years, it has be-
come clear that atherosclerosis is a chronic inflammatory disease. Cells
of both the innate and adaptive immune system, such as macrophages,
dendritic cells (DCs), T and B lymphocytes, are present in athero-
sclerotic plaques and are involved in the progression of the disease
[3,4]. While there is still debate about the specific role of certain cell
types in atherosclerosis, the general consensus is that T helper 1 (Th1)
CD4+ T cells are pro-atherogenic, while regulatory T and B cells (Tregs
and Bregs, respectively) are protective [5,6]. Tregs are known to be
vital for immune suppression, regulation, and resolution of
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inflammation after infection [7]. They form a subset of CD4+ T cells
that express the transcription factor forkhead box P3 (FOXP3) and the
IL-2 receptor α chain (CD25). Tregs mediate tolerance by the produc-
tion of the anti-inflammatory cytokines interleukin (IL)-10 and trans-
forming growth factor (TGF)-β [8], consuming IL-2, interrupting ef-
fector T cell metabolism or even lysing effector T cells [9]. In many
inflammatorydiseases, including atherosclerosis [10–12], Tregs have a
reduced function or ability to proliferate. Current strategies for treat-
ment of such disorders involve systemic suppression of inflammation
with drugs or by selective cell depletion. However, these therapies can
result in severe side effects, especially upon long-term treatment
[13–15]. A more specific strategy would be to design a vaccine that
induces specific tolerance through induction of Tregs that recognize the
autoantigens involved in inflammatory diseases. LDL has been identi-
fied as the most relevant antigen in atherosclerosis, as it is important in
the initiation of atherosclerosis [2,16]. Indeed, oxLDL-specific T cells
have been found in human atherosclerotic plaques [17], and antibodies
against ApoB100 (the apolipoprotein of LDL) have been identified in
patients with cardiovascular disease [18–20]. LDL, ApoB100, ApoB100-
derived peptides and antibodies against ApoB100-derived peptides
have successfully been used as vaccine targets in mice [21–28].
While these studies show a reduction in atherosclerotic plaque
formation in mice, only a few have been designed with the goal of in-
ducing antigen-specific Tregs [29] or using complex formulations [24].
To our knowledge, there are no reports about the use of athero-pro-
tective antigens with advanced drug delivery formulations. Im-
munotherapy with so-called tolerogenic DCs (DCs pulsed ex vivo with
antigens and IL-10 or TGF-β) or oxLDL-pulsed (apoptotic) DCs have
been successful at inducing Tregs. However, these treatments are ex-
pensive, as they require ex vivo isolation and long-term culturing of DCs
under GMP conditions [30–32]. Moreover, there is evidence that DCs
induced in this way can lose their migratory and T cell activation po-
tential or can even revert to a pro-inflammatory phenotype in vivo [33].
Therefore, there is a need for vaccine formulations that induce tolero-
genic DCs and ApoB100-specific Tregs in vivo.
Liposomes are established delivery vehicles which can deliver a
drug or antigen directly into the cell [34]. Moreover, their properties
and contents can be fine-tuned to the therapy. For instance, it has been
shown that anionic liposomes composed of phosphatidylserine (PS)
resemble apoptotic cells (PS becomes exposed on the surface of apop-
totic cells [35]). Through SR-mediated uptake by antigen-presenting
cells, PS-containing liposomes mediate an anti-inflammatory effect in
diabetic and edema mouse models [36,37]. Furthermore, empty PS li-
posomes used in the treatment of atherosclerosis reduced plaque size
and cellular content to a similar extent as injection of apoptotic cells
[38]. In contrast, cationic liposomes are known to be pro-inflammatory,
which is advantageous for vaccination against infectious diseases or the
treatment of cancer [39,40].
Here we assessed whether we can use liposomal formulations to
induce antigen-specific Tregs, and subsequently use these liposomes to
encapsulate a newly identified ApoB100-derived peptide to provide
protection against atherosclerosis. We report that phosphatidylglycerol
(PG)-containing liposomes mediate a superior antigen-specific Treg
response compared to the free antigen, PS liposomes or cationic lipo-
somes. Moreover, we show that an SR-independent pathway for PG-
containing liposomes mediates the induction of Tregs. Furthermore, we
identified a major-histocompatibility complex (MHC)-II-restricted
ApoB100-derived peptide using a peptidomics strategy, which, when
encapsulated in DSPG liposomes, successfully reduced atherosclerotic
plaque formation in an atherosclerosis mouse model.
2. Materials and methods
2.1. Materials
The lipids 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-
distearoyl-sn-glycero-3-phosphoglycerol (DSPG), 1,2-dipalmitoyl-sn-
glycero-3-phospho-L-serine (DPPS), 1,2-dipalmitoyl-3-trimethylammo-
nium-propane (DPTAP), and 1,2-dipalmitoyl-sn-glycero-3-phos-
phoethanolamine-N-(lissamine rhodamine B sulfonyl) (DPPE-Rho) were
obtained from Avanti Polar Lipids (Alabaster, AL, USA). Cholesterol
was purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). The
ovalbumin-derived peptide OVA323 (ISQAVHAAHAEINEAGR) was
obtained from Invivogen (San Diego, California, USA). The ApoB100-
derived peptide p3500 (LSQEYSGSVANEANV) was synthesized by
GenScript (Piscataway, New Jersey, USA). Polycarbonate track-etched
membranes with a pore size of 400 nm and 200 nm were obtained from
Millipore (Kent, UK).
For cell culture, Ca2+- and Mg2+-free phosphate-buffered saline
(PBS), Iscove's Modified Dulbecco's Medium (IMDM), Roswell Park
Memorial Institute Medium (RPMI 1640), L-glutamine, and penicillin/
streptomycin were purchased from Lonza (Basel, Switzerland).
Lipopolysaccharide (LPS) extracted from Salmonella Typhosa, phorbol
12-myristate 13-acetate (PMA), ionomycin, brefeldin A, β-mercap-
toethanol, and polyinosinic acid (poly I) were purchased from Sigma-
Aldrich (Zwijndrecht, the Netherlands). Granulocyte-macrophage
colony-stimulating factor (GM-CSF) was purchased from PeptroTech
(London, UK). Human C1q was purchased from Abcam (Cambridge,
UK). Fetal calf serum (FCS) was purchased from GE Healthcare (Little
Chalfont, UK). Human C1q-depleted serum and normal human serum
were a generous gift from Dr. F. A. Ossendorp (Department of
Immunohematology and Blood Transfusion, Leiden University Medical
Centre).
The antibodies CD4-PerCP (RM4–5), Ly-6G (1A8) and NK1.1
(PK136) were purchased from BD Biosciences (NJ, USA). CD4-APC
(GK1.5), CD4-FITC (GK1.5) and Thy1.2-PerCP-Cy5.5 (53-2.1) were
purchased from Biolegend (CA, USA). CD11b-eFluor450 (M1/70),
CD25-FITC (PC61.5), CD45.1-eFluor450 (A20), CD45.1-PE (A20),
Fixable viability dye-APC-eFluor780, Fixable viability dye-eFluor506,
FOXP3-eFluor450 (FJK-16 s), IFNγ-PE (XMG1.2), IL-10-APC (JES5-
16E3), IL-17A-PE (eBio17B7), IL-4-APC (11B11), Ki67-FITC (SolA15),
Ly-6C-PerCP-Cy5.5 (HK1.4), Thy1.2-PE-Cy7 (53–2.1), and FOXP3/
transcription factor staining kit were purchased from eBioscience
(Thermofisher Scientific, MA, USA). CCR2-APC (#475301) was pur-
chased from R&D systems (MN, USA).
For sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting (WB), Laemmli sample buffer,
Precision Plus Protein™ all blue prestained protein standards, Mini-
PROTEAN® Tetra vertical electrophoresis cell, Mini Trans-Blot® cell,
blot absorbent filter paper, and 4–20% Mini-PROTEAN® precast gels
were purchased from Bio-Rad (Veenendaal, the Netherlands). Bovine
serum albumin (BSA), Polysorbate 20, tris-glycine-SDS buffer 10×
concentrate, tris(hydroxymethyl)aminomethane, glycine, and 3-amino-
9-ethylcarbazole (AEC) staining kit were purchased from Sigma-Aldrich
(Zwijndrecht, the Netherlands). Nitrocellulose membrane with a
0.45 μm pore size was obtained from GE Healthcare (Little Chalfont,
UK). Mouse monoclonal biotinylated anti-C1q antibody (JL-1) was
purchased from Abcam (Cambridge, UK). Streptavidin-horseradish
peroxidase (HRP) was purchased from Thermofisher Scientific (MA,
USA).
Optimal cutting temperature (OCT) formulation Tissue-Tek® was
obtained from Sakura Finetek (CA, USA). For immunohistochemical
staining, Hematoxylin, Oil-Red-O, Sirius Red, and anti-rat IgG (whole
molecule)–alkaline phosphatase antibody produced in goat were pur-
chased from Sigma-Aldrich (Zwijndrecht, the Netherlands), rat anti-
mouse macrophages/monocytes antibody (MOMA2) was purchased
from Bio-Rad (Veenendaal, the Netherlands). 5-bromo-4-chloro-3-in-
dolyl phosphate (BCIP)/nitro blue tetrazolium (NBT) substrate system
buffer was purchased from DAKO (Agilent, CA, USA).
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2.2. Animals
C57BL/6, OT-II transgenic, T-cell immunoglobulin- and mucin-do-
main-containing molecule 4 (TIM4)−/− and LDLr−/− mice on a
C57BL/6 background were purchased from Jackson Laboratory (CA,
USA), bred in-house under standard laboratory conditions, and pro-
vided with food and water ad libitum. LDLr−/− mice were fed a
Western-type diet (WTD) containing 0.25% cholesterol and 15% cocoa
butter (Special Diet Services, Essex, UK). All animal work was per-
formed in compliance with the Dutch government guidelines and the
Directive 2010/63/EU of the European Parliament. Experiments were
approved by the Ethics Committee for Animal Experiments of Leiden
University.
2.3. Bone marrow-derived dendritic cells (BMDCs)
Bone marrow was isolated from the tibias and femurs of C57BL/6 or
TIM4−/− mice. A single-cell suspension of bone marrow cells was ob-
tained by using a 70-μm cell strainer (Greiner Bio-One B.V., Alphen aan
den Rijn, NL). The cells were cultured in IMDM (Lonza) supplemented
with 2mM L-glutamine, 8% (v/v) FCS, 100 U/mL penicillin/strepto-
mycin (Lonza), and 50 μM β-mercaptoethanol (Sigma) at 37 °C and 5%
CO2 in 95mm Petri dishes (Greiner Bio-One B.V., Alphen aan den Rijn,
NL) and 20 ng/mL GM-CSF (PeproTech) for 10 days. Medium was re-
freshed every other day.
2.4. Immunoprecipitation
BMDCs were incubated with 10% serum from LDLr−/− mice on a
WTD activated with 0.1 μg/mL LPS. Affinity-purification of MHC-II (I-
Ab) molecules from BMDCs and subsequent peptide elution was per-
formed as described previously [41]. Approximately 50×106 BMDCs
were lysed in 0.5mL lysis buffer (50mM Tris-Cl pH 8.0, 150mM NaCl,
5 mM Ethylenediaminetetraacetic acid (EDTA), 0.5% Zwittergent 3–12
(N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate) and pro-
tease inhibitor (Complete, Roche Applied Science)) for 2 h at 0 °C [41].
Lysates were centrifuged for 10min at 2500×g and for 45min at
31000 x g to remove nuclei and other insoluble material, respectively.
Lysates were passed through a 50 μL CL-4B Sepharose column (in a
standard yellow tip equipped with a filter) to pre-clear the lysate and
subsequently passed through a 50 μL column containing 125 μg pan
class II (Y3P) IgG coupled to protein G Sepharose [41]. The Y3P column
was subsequently washed with 250 μL of lysis buffer, 250 μL of low salt
buffer (20mM Tris-Cl pH 8.0, 120mM NaCl), 100 μL of high salt buffer
(20mM Tris-Cl pH 8.0, 1M NaCl), and finally with 250 μL of the low
salt buffer. I-Ab and peptides were eluted with 250 μL of 10% acetic
acid, diluted with 1mL of 0.1% trifluoroacetic acid (TFA) and purified
by SPE (Oasis HLB, Waters) by sequential elution with 20%, 30% and
40% acetonitrile in 0.1% TFA to recover MHC peptide molecules.
2.5. Mass spectrometry
MHC peptides were analyzed by using an Easy nLC1000 (Thermo,
Bremen, Germany) coupled to a Q-Exactive mass spectrometer
(Thermo). The injection was done onto a homemade pre-column
(100 μm×15mm; Reprosil-Pur C18-AQ 3 μm, Dr. Maisch,
Ammerbuch, Germany) and elution via a homemade analytical column
(15 cm×50 μm; Reprosil-Pur C18-AQ 3 μm). The gradient was 0% to
30% solvent B (90% ACN/0.1% TFA) in 120min. The analytical column
was drawn to a tip of around 5 μm and acted as the electrospray needle
of the MS source. The Q-Exactive mass spectrometer was operated in
top10-mode. Parameters were as follows: full scan, 70,000 resolution,
3,000,000 AGC target, max fill time 20ms; MS/MS, 35,000 resolution,
100,000 AGC target, 60ms max fill time, 17,400 intensity threshold.
Apex trigger was set to 1–5 s and allowed charges were 2–5. Proteome
Discoverer version 2.1 was used for peptide and protein identification,
using the mascot node for identification, using mascot version 2.2.04
with the UniProt/Mouse database (51,374 entries). Methionine oxida-
tion (on methionine) and cysteinylation (on cysteine) were set as
variable modification. Precursor ion mass tolerance was set to 10 ppm.
MS/MS fragment tolerance was 20 mmu. ApoB100-derived peptides as
proposed by the software are shown in Table S1 and were manually
assessed. The identified ApoB100 peptides were screened in silico
(www.IEDB.org) for their ability to bind to MHC-II (Table S2). The
correct assignment of the candidate peptide of sequence LSQEYSGSV-
ANEAN was confirmed by matching of the MS/MS spectrum of eluted
peptide and its synthetic peptide counterpart (Fig. S1).
2.6. Liposome preparation
Liposomes were prepared by using the thin film dehydration-rehy-
dration method, as described previously [42]. Briefly, DSPC
(Tm=54.9 °C [43]), a charged lipid (DSPG (Tm=54.4 °C [44]), DPPS
(Tm=55 °C [45]), or DPTAP (Tm=52.8 °C [46])) and cholesterol were
dissolved in chloroform and mixed in a round-bottom flask at a molar
ratio of 4:1:2 DSPC:charged lipid:cholesterol to obtain a final lipid
concentration of 10mg/mL. The chloroform was evaporated in a rotary
evaporator (Rotavapor R-210, Büchi, Switzerland) for 1 h at 40 °C. The
lipid film was rehydrated with 250 μg OVA323 dissolved in 1mL Milli-
Q water and homogenized by rotation at 60 °C by using glass beads.
Next, the liposome dispersion was snap-frozen in liquid nitrogen, fol-
lowed by freeze-drying overnight (Christ alpha 1–2 freeze-dryer, Os-
terode, Germany). The freeze-dried lipid cake was slowly rehydrated by
using 10mM phosphate buffer (PB), pH 7.4 at 60 °C; two volumes of
500 μL and one volume of 1000 μL PB were successively added, with
intervals of 30min between each addition. The mixture was vortexed
well between each hydration step, and the resulting dispersion was kept
at 60 °C for at least 1 h. The multilamellar vesicles were sized by high-
pressure extrusion at 60 °C (LIPEX Extruder, Northern Lipids Inc., Ca-
nada). To obtain monodisperse liposomes, the liposome mixture was
passed four times through stacked 400 nm and 200 nm pore size
membranes. To separate non-encapsulated OVA323 from the lipo-
somes, liposomes were washed by using a Vivaspin 2 centrifuge mem-
brane concentrator (MWCO 300 kDa, Sartorius, Göttingen, Germany).
DSPG-containing liposomes encapsulating the ApoB100-derived pep-
tide p3500 were prepared in the same way as OVA323 liposomes,
where the lipid film was rehydrated with 250 μg p3500 dissolved in
1mL Milli-Q water. To prepare fluorescently labeled liposomes, 0.5 mol
% of DSPC was replaced with DPPE-Rho. Liposomes were stored at 4 °C
and used for further experiments within 2 weeks.
2.7. Liposome characterization
The Z-average diameter (Zave) and polydispersity index (PDI) of the
liposomes were measured by dynamic light scattering (DLS) using a
NanoZS Zetasizer (Malvern Ltd., Malvern, UK). Zeta-potential was de-
termined by using laser Doppler electrophoresis using the same in-
strument. For measurements, the liposomes were diluted 100-fold in
10mM phosphate buffer at pH 7.4 to a total volume of 1mL. To de-
termine the concentration of loaded OVA323, the peptide was sepa-
rated from liposomes by using a modified Bligh-Dyer method, as de-
scribed previously [42]. Briefly, 100 μL of aqueous liposomal dispersion
or a known concentration of free peptide as control was mixed with
250 μL methanol and 125 μL chloroform and vortexed briefly. 250 μL of
0.1M HCl and 125 chloroform was added and the mixture was vortexed
again. This was then centrifuged for 5min at 1500 rpm to separate the
water-methanol phase (containing the peptide) from the chloroform
phase. The upper water-methanol phase was collected and analyzed by
reversed phase UPLC (Waters ACQUITY UPLC, Waters, MA, USA). For
this, 5 μL of the sample was injected into a 1.7 μm BEH C18 column
(2.1× 50mm, Waters ACQUITY UPLC, Waters, MA, USA). The column
temperature and the temperature of the sample were set at 40 °C and
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4 °C respectively. The mobile phases were Milli-Q water with 0.1% TFA
(solvent A) and acetonitrile with 0.1% TFA (solvent B). For detection,
the mobile phases were applied in a linear gradient from 5% to 95%
solvent B over 5min at a flow rate of 0.370mL/min. Peptides were
detected by absorbance at 220 nm using an ACQUITY UPLC TUV de-
tector (Waters ACQUITY UPLC, Waters, MA, USA).
2.8. Protein corona analysis
To characterize the formation of a protein corona on liposomes, li-
posomes were diluted to a lipid concentration of 0.1 mg/mL and in-
cubated for 1 h at 37 °C with FCS or 10 μg/mL C1q in PB. Liposomes
were washed three times and concentrated with a Vivaspin 500 cen-
trifuge membrane concentrator (MWCO 1000 kDa, Sartorius,
Goettingen, Germany) to remove unbound proteins, leaving the ‘hard’
protein corona [47]. Size, PDI, and zeta-potential of liposomes were
measured with a NanoZS Zetasizer (Malvern Ltd., Malvern, UK). SDS-
PAGE was performed according to the manufacturer's instructions.
Samples and MW standards were diluted 1:1 in reducing Laemmli
buffer and 10 μL of sample was loaded per lane. Gels were stained with
Coomassie Blue and analyzed by using a scanner (GS-900™, Bio-Rad,
Veenendaal, the Netherlands) and Image Lab™ software (Bio-Rad,
Veenendaal, the Netherlands). For WB for C1q, SDS-PAGE was first
carried out as described above, and proteins were transferred by using
the wet blotting method according to the manufacturer's instructions.
Blots were blocked overnight at 4 °C with PBS containing 2% BSA and
0.5% polysorbate 20. Subsequently, blots were incubated for 1 h at
room temperature with biotinylated anti-C1q antibody diluted 1000-
fold in blocking buffer, followed by 1-h incubation at room temperature
with streptavidin-HRP diluted 1000-fold in blocking buffer. An AEC
staining kit was used to develop the blots, and we analyzed blots with a
scanner and Image Lab™ software.
2.9. Liposome uptake by BMDCs
BMDCs were cultured as described above. After 10 days of culture,
50,000 BMDCs were plated in 96-well plates (Greiner Bio-One B.V.,
Alphen aan den Rijn, Netherlands) and fluorescently labeled liposomes
or controls were added at a concentration of 0.1 μg/mL OVA323 in
different media. To block SR-mediated uptake, 250 μg/mL poly I was
added. After 4 h of incubation at 37 °C and 5% CO2, excess liposomes
were removed by washing the cells several times with IMDM. Cultures
were supplemented with 20 ng/mL GM-CSF and incubated overnight.
Cells were analyzed by flow cytometry (CytoFLEX S, Beckman Coulter,
CA, USA). BMDCs were stained for CD11c and viability. The presence of
the fluorescent label in the liposomes indicated uptake by BMDCs. Data
were analyzed by using FlowJo software (Treestar, OR, USA).
2.10. In vitro Treg induction by liposome-pulsed BMDCs
Wild-type (WT) or TIM4−/− BMDCs were cultured as described
above, and activated for 4 h with liposomes or controls in different
media. Spleens were removed from OT-II mice and strained through a
70-μm cell strainer to obtain a single-cell suspension. Erythrocytes were
lysed with Ammonium-Chloride-Potassium (ACK) lysis buffer (0.15M
NH4Cl, 1 mM KHCO3, 0.1mM Na2EDTA; pH 7.3). CD4+ T cells were
isolated using a CD4+ T cell isolation kit (Miltenyi Biotec B.V., Leiden,
Netherlands) according to the manufacturer's protocol. After incuba-
tion, BMDCs were thoroughly washed with PBS to remove any free li-
posomes, and 100,000 CD4+ T cells were added to obtain a number
ratio of 2:1 CD4+ T cells:BMDCs. Co-cultures were cultured for 72 h in
complete RPMI 1640 medium supplemented with 2mM glutamine,
10% FCS, 100 U/mL penicillin/streptomycin, and 50 μM β-mercap-
toethanol. Cells were stained for Thy1.2, CD4, viability, FOXP3, and
Ki67, and analyzed by flow cytometry (CytoFLEX S, Beckman Coulter,
CA, USA). Data were analyzed by using FlowJo software (Treestar, OR,
USA).
2.11. Analysis of antigen-specific CD4+ T cell responses in vivo
12-week-old male C57BL/6 mice were randomized into 5 groups.
On day 0, all groups received splenocytes isolated from a female OT-II
transgenic mouse equivalent to 500,000 CD45.1+CD4+ T cells via the
tail vein. On day 1, mice were immunized intravenously (i.v.) with a
single injection of either PBS, 1 nmol free OVA323 in PBS, or liposomes
containing 1 nmol OVA323 in PBS, in a total volume of 200 μL via the
tail vein. Seven days after immunization, a small amount of blood was
collected from the mice via the tail. Blood samples were lysed and
stained for Thy1.2, CD4, CD45.1 and viability, and samples were ana-
lyzed by flow cytometry (Cytoflex S, Beckman Coulter, Indiana, USA).
On day 8, mice were sacrificed by cervical dislocation and spleens and
inguinal lymph nodes (iLNs) were immediately removed. Organs were
processed and stained for CD4, CD45.1, Thy1.2, viability, Ki67, CD25
and FOXP3 and measured by flow cytometry. To measure cytokine
production, splenocytes were stimulated ex vivo with PMA (50 ng/mL)
and Ionomycin (500 ng/mL). After 1-h brefeldin A (3 μg/mL) was added
and cells were incubated for a further 5 h. Cells were subsequently
stained for Thy1.2, CD4, CD45.1, viability, IFN-γ, IL-17, IL-4 and IL-10
and analyzed by flow cytometry.
2.12. Analysis of atherosclerosis in mice
Eight- to 14-week-old male LDLr−/− mice were randomized into 3
groups of 9 mice. Mice were fed a WTD for 10weeks to induce ather-
osclerosis. During this time, mice were immunized at week 0, 3, 6 and 9
via i.p. injection with either PBS, 10 nmol of free p3500 peptide in PBS,
0.5 mg DSPG-liposomes in PBS, or 0.5mg DSPG-liposomes containing
10 nmol of p3500 in PBS, in a total volume of 200 μL. After 10 weeks,
mice were euthanized by a subcutaneous injection (120 μL) of a cocktail
containing ketamine (40mg/mL), atropine (50 μg/mL), and sedazine
(6.25mg/mL). Mice were exsanguinated and perfused with PBS. For
flow cytometry, aortas were harvested and cut into small pieces. These
were incubated for 30min at 37 °C with 450 U/mL collagenase I,
250 U/mL collagenase XI, 120 U/mL DNAse, and 120 U/mL hyalur-
onidase, and strained through a 70-μm cell strainer to obtain a single-
cell suspension. Cells were stained for Thy1.2, CD4, CD8 and viability.
Hearts were harvested and fixed frozen in OCT formulation at −80 °C.
Hearts were subsequently cryosectioned horizontally to the aortic axis
and towards the aortic arch. Upon identification of the aortic root,
defined by the trivalve leaflets, 10 μm sections were collected. Sections
were stained for Oil-Red-O as previously described [48] to visualize
lipid-rich plaques. Macrophages in the plaques were stained using
MOMA2 staining as previously described [49]. Collagen in the plaques
was stained using Sirius Red staining, as previously described [50]. All
stainings were analyzed by microscopy using Leica QWin software on a
Leica DM-RE microscope (Leica, Imaging Systems, UK). Briefly, the area
stained positively for Oil-Red-O, expressed as μm2, was determined for
the section with the largest lesion, and the two flanking sections to
estimate the average plaque size. The average percentage of macro-
phages in the plaque was determined by dividing the area positive for
the MOMA2 staining by the total plaque area for the 3 largest sub-
sequent sections. Sirius Red staining was visualized under polarized
light [51], and the percentage of collagen was calculated by dividing
the area positive for the Sirius Red staining by the total plaque area for
the 3 largest subsequent sections. Blood samples were prepared for
determination of serum cholesterol levels as previously described [30].
2.13. Statistical analysis
Results were analyzed using one-way or two-way ANOVA, followed
by Bonferroni's multiple comparisons test and was performed using
GraphPad Prism version 7.00 for Windows (GraphPad Software, CA,
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USA).
3. Results
3.1. Preparation of liposomes
Anionic liposomes are associated with tolerance induction [36,37],
although it is unclear whether this is merely due to the negative charge
or the specific anionic head group.
In order to determine which anionic phospholipid would be most
effective for the induction of antigen-specific Tregs, we prepared lipo-
somes containing DSPG or DPPS, ensuring all other physicochemical
characteristics like size, zeta-potential and rigidity remained similar. As
a positive control for pro-inflammatory responses, we made DPTAP-
containing liposomes. Liposomes were prepared with DSPC, charged
lipids (DSPG, DPPS or DPTAP) and cholesterol at a molar ratio of 4:1:2
with an initial concentration of 250 μg/mL OVA323. The liposomes
were around 165 nm in size and were monodisperse, with a PDI around
0.1 (Table 1). As expected, the zeta potential of the liposomes was
negative for both anionic liposomal formulations and positive for the
DPTAP liposomes. The loading efficiency (LE) of OVA323 was between
10 and 15% for the anionic liposomes and almost 30% for the cationic
liposomes. The addition of a small amount of fluorescently labeled
DPPE did not alter the liposomal properties (Table S3), and replacing
OVA323 with the athero-specific ApoB100-derived peptide p3500 did
not alter the properties of DSPG-liposomes (Table S4).
3.2. Liposomes induce strong antigen-specific CD4+ T cell responses in mice
To determine the effect of liposomes on antigen-specific CD4+ T cell
expansion in vivo, a single immunization with OVA323-containing li-
posomes or free OVA323 was performed in mice, which had received an
adoptive transfer of OT-II splenocytes one day prior to immunization.
All liposomal formulations induced proliferation of antigen-specific
CD45.1+CD4+ T cells in the blood of mice just 7 days after im-
munization (Fig. 1A, D, E, F, and G). In contrast, free OVA323 induced
almost no antigen-specific CD4+ T cell proliferation, comparable to
PBS. We observed very similar results in the spleens and iLNs on day 8
(Fig. 1B and C). The antigen-specific CD4+ T cell proliferation induced
by cationic liposomes tended to be increased, albeit not significant
compared to OVA-specific CD4+ T-cell responses induced by anionic
liposomes (Fig. S2).
3.3. DSPG-liposomes induce antigen-specific Tregs in vivo
To uncover the type of OVA323-specific CD4+ T cells induced by the
liposomes in mice, antigen-specific (CD45.1+CD4+CD25+FOXP3+)
Tregs were measured by flow cytometry after immunization (Fig. 2A, B,
and C). We found comparable percentages of non-specific Treg popula-
tions (CD45.1−CD4+CD25+FOXP3+) in all mice (Fig. S3). DSPG-lipo-
somes encapsulating OVA323 induced the highest percentage of antigen-
specific Tregs, which was significantly higher than the background Treg
response after injection of free OVA323. Surprisingly, DPPS-liposomes
were not as efficient at Treg induction as DSPG-liposomes, but they did
show a non-significant increase in Tregs compared to free OVA323.
DPTAP-liposomes did not alter Treg responses as compared to the
background. We also measured antigen-specific intracellular cytokine
responses by flow cytometry after restimulation with PMA and iono-
mycin (Fig. 2D, E, F, and G). DPTAP-liposomes greatly increased pro-
inflammatory cytokine production (interferon (IFN)-γ and IL-17) of the
antigen-specific CD4+ T cells, while both anionic liposomes induced
almost no production of these cytokines. There were no differences in IL-
4 or IL-10 production in any of the groups.
3.4. Anionic liposomes attract C1q from serum and are taken up by SRs
While both anionic liposomal formulations had similar physico-
chemical properties and could induce Tregs, DSPG-containing lipo-
somes were clearly more potent. The cationic DPTAP liposomes in-
duced no Tregs. We hypothesized that a protein corona around the
liposomes could be responsible for the differences in in vivo im-
munological responses. To assess the formation of a protein corona, we
incubated the anionic liposomes in FCS for 1 h at 37 °C and washed
them to remove any unbound proteins, leaving the ‘hard’ protein
corona. SDS-PAGE analysis showed that the liposomes attract proteins
from FCS (Fig. S4A). Several serum proteins can bind to nanoparticles,
including complement proteins [52]. Of these complement proteins,
C1q is especially interesting since it can bind to various receptors [53].
Notably, binding of C1q to PS on apoptotic cells leads to recognition
and clearance by phagocytic cells via SRs [54–56]. To test whether the
protein corona or C1q is important for uptake of liposomes by BMDCs
and Treg induction, we measured uptake of fluorescently labeled lipo-
somes by BMDCs in the absence of serum, or in medium containing
either 8% FCS or C1q. We also assessed OT-II FOXP3+Ki67+CD4+ T
cell induction by these BMDCs. Both DSPG- and DPPS-liposomes
showed an uptake of< 10% in the absence of FCS or C1q, however, the
uptake of DPPS-liposomes was around 10-fold lower in this condition
(Fig. 3A). Addition of C1q or FCS significantly increased uptake of both
liposomes, with DSPG-liposomes showing significantly higher uptake
than DPPS-liposomes in normal serum conditions at the concentration
of lipids we examined (Fig. 3A). Moreover, for DSPG-liposomes, de-
pletion of C1q from serum significantly reduced uptake, which was
remedied by reconstituting C1q (Fig. S5). Liposomes in the presence of
serum significantly increased Treg induction compared to serum-free
conditions (Fig. 3B). The in vitro data supports the in vivo findings, i.e.,
in the presence of serum, both liposomes enhanced Treg induction
compared to free OVA323, and DSPG liposomes were more potent. It
should be noted that, although DCs can produce C1q [57], the short
incubation time of 4 h should not allow for a significant production of
C1q. We also assessed whether TIM4, a known receptor for apoptotic
cells that plays an important role in atherosclerosis [58], plays a role in
mediating the uptake of our liposomes and induction of Tregs. How-
ever, TIM4−/− BMDCs showed no differences in liposome uptake and
Treg induction compared to WT BMDC (Fig. S6).
Importantly, C1q is present in FCS and in the protein corona of both
DSPG- and DPPS-liposomes, as measured by SDS and WB (Fig. 4A, Fig.
S4B). To test the effect of FCS and C1q binding to the liposomes on their
physicochemical properties, we incubated liposomes either with FCS in
PB or with C1q in PB, washed them, and analyzed them using DLS.
Either condition significantly increased the size of both DSPG- and
DPPS-liposomes as compared to a protein-free medium. However, there
were no signs of severe aggregation of liposomes, as the size remained
below 200 nm for all groups (Fig. 4B, E, and F). For both liposomal
formulations, C1q binding moderately but significantly increased PDI
and reduced the negative zeta-potential of the liposomes. FCS binding
enhanced this effect even further (Fig. 4C and D).
As C1q has been reported to mediate SR-mediated uptake, we
evaluated the role of SR-mediated uptake of liposomes by BMDCs by
measuring uptake of fluorescently labeled liposomes in the presence of
Table 1
Physicochemical properties of OVA323-containing liposomes composed of
4:1:2M ratio DSPC:charged lipid:chol.
Charged lipid Zave (nm)a PDI Zeta-potential
(mV)
% LEb
DSPG 167.3 ± 11.8 0.08 ± 0.04 −54.4 ± 5.5 10.6 ± 3.9
DPPS 165.4 ± 15.7 0.12 ± 0.05 −54.0 ± 6.4 14.7 ± 4.7
DPTAP 166.9 ± 14.9 0.09 ± 0.04 33.7 ± 3.7 27.6 ± 8.5
a Z-average diameter (Zave), mean ± SD, n=12.
b %LE was calculated as the total amount of peptide before extrusion/total
amount of peptide after purification * 100%.
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poly I, a non-selective SR antagonist [59], in both medium containing
8% FCS or serum-free medium Blocking of SR-mediated uptake in the
presence of serum reduced uptake of both DSPG- and DPPS-liposomes
to the levels of “- serum”, indicating that SRs are responsible for the
uptake of most of the liposomes by BMDCs under normal serum con-
ditions (Fig. 5). The addition of poly I did not alter the uptake of li-
posomes in serum-free conditions, suggesting that bare liposomes did
not interact with SRs (Fig. 5).
3.5. DSPG-liposomes encapsulating an atherosclerosis-specific peptide
significantly reduce plaque formation and increase plaque stability in
atherosclerotic mice
Tolerance induction against atherosclerosis using peptides targeted
against the main antigen in atherosclerosis, LDL, has yielded some
success [23–28]. We hypothesized that encapsulation of an athero-
sclerosis-specific peptide in DSPG-liposomes would reduce athero-
sclerosis progression more efficiently than the free peptide, via induc-
tion of antigen-specific Tregs. The protein surrounding LDL, ApoB100,
is a large protein (515 kDa in humans, 509 kDa in mice) containing
several potential CD4+ T cell epitopes. To identify a relevant ApoB100
peptide for immunization, we eluted MHC-II restricted peptides from
BMDCs exposed to hypercholesterolemic serum. We identified several
ApoB100-derived peptides using our peptidomics strategy (Table S1).
Based on the predicted MHC-II binding (Table S2) we selected the
peptide ApoB1003500–3514 (p3500) and successfully loaded it into
DSPG-liposomes (Table S4). LDLr−/− mice on a WTD were selected as a
model for diet-induced atherosclerosis [12]. The mice were fed a WTD
for 10weeks, during which they were injected i.p. four times with PBS,
10 nmol of free p3500 or 10 nmol of p3500 encapsulated in DSPG-li-
posomes (DSPG/p3500-liposomes). Neutral lipid staining (Oil-Red-O)
of the aortic valve area of the heart, which is used to quantify the lipid-
rich atherosclerotic lesion, showed that treatment with p3500-loaded
DSPG-liposomes significantly reduced the lesion area by 50% (Fig. 6A
and B). As expected, all mice gained weight due to the WTD, but there
were no differences between the groups (Fig. 6C). Similarly, serum
cholesterol levels were elevated in all groups because of the WTD. In-
terestingly, only the group of mice that received the DSPG/p3500
treatment had significantly lower levels of serum cholesterol compared
to the PBS control group (Fig. 6D). The aortic sections were further
stained for macrophage content, which is an indicator of immune ac-
tivation [60]. Differences in macrophage content between the groups
were not significant, although there was a trend towards lower mac-
rophage content in the mice immunized with liposomes (Fig. 6B and E),
which could be (partially) responsible for the reduction in plaque size.
Furthermore, there were significantly fewer CD8+ T cells present in the
aorta of mice injected with liposomes (Fig. S7B). Levels of the in-
flammatory CCR2+Ly-6Chi monocytes were unchanged in the blood of
mice in all groups (Fig. S8A), further indicating that there was no in-
creased inflammation. Finally, the collagen content in the lesions was
assessed, as an indication of lesion stability [51]. Only the mice re-
ceiving DSPG/p3500 presented with a higher collagen content in their
lesions (Fig. 6B and F), suggesting a more stable plaque. Total Treg
levels were the same in all groups (Fig. S8B).
Previous work suggests injection of PS-containing liposomes can
affect atherosclerosis development [38]. Therefore we investigated
Fig. 1. Expansion of OVA323-specific CD4+ T cells
in blood, spleens, and iLNs of mice after i.v. injection
of OVA323-containing liposomes. (A) CD45.1+
CD4+ T cells in blood (day 7), (B) inguinal LNs (day
8) and (C) spleen (day 8) of mice after immunization
with DSPG-, DPPS-, or DPTAP-liposomes containing
the OVA323 peptide, or PBS or free OVA323 peptide.
Representative flow cytometry plots of pre-gated
CD4+ T-cells in the blood mice 7 days after im-
munization with (D) free OVA323, (E) DSPG/
OVA323-, (F) DPPS/OVA323-, and (G) DPTAP/
OVA323-liposomes. *p < .05, **p < .01, compared
to free OVA323 determined by one-way ANOVA and
Bonferroni's multiple comparisons test. No sig-
nificant differences were found between the different
liposomal formulations. Representative example of 2
independent experiments.
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whether empty DSPG-liposomes may have mediated the decrease serum
cholesterol levels and inhibition of atherosclerosis. However, we found
no differences in serum cholesterol, plaque size, or immune activation
upon immunization with DSPG liposomes compared to PBS (Fig. S9).
Thus, the results suggest that DSPG/p3500-liposomes are able to reduce
the growth of atherosclerotic lesions, lower serum cholesterol levels,
and stabilize atherosclerotic plaques.
4. Discussion & conclusion
Atherosclerosis is the main underlying pathology for cardiovascular
disease and is one of the leading causes of death worldwide [1]. While
vaccination against atherosclerosis has been successful in murine
models [23–28], a major challenge is the induction of antigen-specific
Tregs in a safe and effective way. Here we introduce DSPG-liposomes as
a peptide antigen carrier to induce regulatory T-cells and as a potential
vaccine against atherosclerosis. Whereas DPTAP-liposomes can induce
strong pro-inflammatory responses, we hypothesized that DSPG- and
DPPS-liposomes lead to immune suppression because of their similarity
to apoptotic cells. OVA323-containing liposomes were prepared with
high-Tm lipids, since rigid liposomes have been shown to enhance APC
uptake [61] and activation [62], and would, therefore, be more potent
at inducing T cell responses compared to fluid-state liposomes. We
show that all liposomes induced expansion of OVA323-specific T cells in
Fig. 2. Induction of OVA323-specific immune responses in iLNs and spleens of mice 8 days after i.v. injection of OVA323-containing liposomes. (A)
CD25+FOXP3+CD4+ T cells from adoptive transfer of CD4+ T cells from an OT-II mouse were detected in iLNs of WT mice after immunization with free OVA323, or
DSPG-, DPPS- or DPTAP-liposomes containing OVA323 peptide. Representative flow cytometry plots of pre-gated CD45.1+CD4+ T-cells in the iLNs of a mouse 8 days
after immunization with (B) DPTAP, or (C) DSPG liposomes. Splenocytes were incubated for 6 h with PMA+ ionomycin and brefeldin A, and subsequently, (D) IFNγ,
(E) IL-17, (F) IL-4 and (G) IL-10 production by antigen-specific CD45.1+CD4+ T cells was analyzed by flow cytometry. Graphs show mean, *p < .05, **p < .01
determined by one-way ANOVA and Bonferroni's multiple comparisons tests. Representative of 2 independent experiments.
Fig. 3. Effect of C1q and FCS on in vitro uptake by
BMDCs and subsequent antigen-specific Treg induc-
tion. (A) Percentage of DCs which have taken up
fluorescently labeled OVA323-loaded DSPG- or
DPPS-containing liposomes after 4 h incubation, as
measured by flow cytometry. Cells were incubated
with liposomes either in serum-free IMDM (white
bars), in IMDM supplemented with FCS (black bars)
or in IMDM supplemented with 10 μg/mL C1q (gray
bars). (B) OT-II FOXP3+Ki67+CD4+ T cells induced
after 3 days co-culture with BMDCs exposed to con-
ditions shown in (A). Graph shows mean ± SD
(n=3), * shows comparison to “- serum” condition
within liposome group, # compares to free
OVA323+ serum. ** p < .01, *** p < .001, ****
p < .0001, # p < .05, ## p < .01 determined by
one-way ANOVA and Bonferroni's multiple compar-
isons test.
N. Benne et al. Journal of Controlled Release 291 (2018) 135–146
141
vivo. The cationic liposomes induced pro-inflammatory cytokines,
which we have also previously observed [42]. Only DSPG-containing
liposomes induced significantly higher numbers of
CD25+FOXP3+CD4+ Tregs compared to free OVA323 in mice. This
was surprising since PS-containing liposomes have been reported to
induce antigen-specific Tregs in a type I diabetes model [36]. In ac-
cordance with our study, however, IL-10 and IL-4 responses were also
unchanged in the diabetes model [36]. A head-to-head comparison of
the effect of PS or PG liposomes complexed with Factor VIII (FVIII) in
vitro showed that PS liposomes significantly reduced CD86 and CD40
expression, important co-activating molecules, in DCs as compared to
free FVIII, while PG liposomes did not [63]. This supports our finding
that DSPG liposomes have a higher potency to expand T cells. Un-
fortunately, T cell proliferation was only measured for PS liposomes,
and Treg levels were not measured in the aforementioned study [63].
We show that DSPG-liposomes are more effectively taken up by BMDCs
in vitro than DPPS-liposomes, which could explain their higher potency
to induce Treg. Regardless, uptake of both liposomes was low (<30%),
which has been observed previously, most likely due to unfavorable
electrostatic interactions with the negatively charged cell surface [64].
The mechanism of uptake could also be responsible for the potency of
the DSPG-liposomes. In vitro and in vivo, liposomes interact with pro-
teins in the physiological medium, resulting in the formation of a
protein corona around the liposomes. Accordingly, we observed that
proteins from serum attached to the liposomes and that the presence of
serum was required for efficient uptake by BMDCs and subsequent Treg
induction. This is in line with other studies that have shown the protein
corona to be essential for the biological function of particles [65]. As
mentioned above, several SRs could be responsible for anionic liposome
uptake, and SR-mediated uptake may lead to immune suppression [66].
We found a significant reduction of uptake for both PG- and PS-
Fig. 4. Binding of C1q and FCS components to DSPG-
and DPPS-liposomes Liposomes were incubated with
8% or 4% FCS for 1 h at 37 °C and subsequently
washed thoroughly to remove all unbound proteins,
leaving only the protein corona. (A) WB of C1q after
SDS-PAGE under reducing conditions. Percentages
indicate the concentration (v/v) of FCS in PB. FCS in
PB (no liposomes) was included as a control.
Complete blot is shown in Fig. S3. (B) Z-average
diameter, (C) PDI, and (D) zeta-potential of samples
in PB (white bars), with bound C1q (gray bars), or
with bound FCS (black bars). (E and F)
Representative Gaussian-smoothed intensity-
weighted size distribution of DSPG- and DPPS-lipo-
somes in PB (solid lines), with bound C1q (dashed
lines) or with bound FCS (dotted lines). (F) Bar
graphs show mean ± SD (n= 3) *p < .05,
**p < .01, ****p < .0001, compared to PB, de-
termined by two-way ANOVA and Bonferroni's
multiple comparisons tests.
Fig. 5. Effect of SR blocking on in vitro uptake of fluorescently labeled anionic
liposomes encapsulating OVA323 by BMDCs. Percentage of DCs which have
taken up fluorescently labeled OVA323-loaded DSPG- or DPPS-containing li-
posomes after 4 h incubation, as measured by flow cytometry. Cells were in-
cubated with liposomes in IMDM supplemented with FCS without SR blocking
(black bars) or with SR blocking using 250 μg/mL poly I (black/Gy bars), or in
serum-free IMDM without poly I (white bars) or with poly I (white/Gy bars).
Graph shows mean ± SD (n=3), ****p < .0001, compared to + serum
within liposome group, determined by two-way ANOVA and Bonferroni's
multiple comparisons tests.
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liposomes in the presence of serum when SR-mediated uptake was
blocked, which was not observed in serum-free conditions, suggesting
that formation of a protein corona is required for SR interactions. PS-
liposomes were entirely dependent on SR function for uptake, whereas
PG-liposomes appear to have at least one additional mechanism of
uptake, and could even interact directly with cells, as there was still
uptake in serum-free conditions. There is evidence of binding of anionic
lipids to apoptotic receptors [37,67–71]. We have so far excluded TIM4
as a receptor for PG- or PS-liposome uptake and Treg induction.
Since the serum protein C1q can bind to PS on apoptotic cells and
lead to clearance via SRs [54–56,72], we tested whether C1q present in
the protein corona of the liposomes was responsible for SR-mediated
uptake and Treg induction. C1q forms part of the C1 complex that is
required for triggering of the classical complement pathway but can
also regulate immunity [53,73]. Complement activation seems to be
dependent on the structure of C1q; when it binds to IgG1, C1q has a
different conformation than when it binds directly to PS exposed on the
cell surface or liposomes [74]. Moreover, there is evidence of viruses
binding C1q as a bridging molecule to evade the immune system and
enhance infection [75–77]. C1q deficiency, either genetic [78] or via
anti-C1q autoantibodies [72], can lead to symptoms almost identical to
systemic lupus erythematosus (SLE). Several other autoimmune dis-
orders have been associated with a dysregulation of the complement
system and specifically C1q deficiencies, including atherosclerosis [79].
We show that C1q is present in the protein corona and binds to anionic
liposomes. This is in accordance with other reports of C1q binding to
PS- [70] and PG-containing liposomes [80]. The addition of C1q in
serum-free conditions completely restored the uptake of both PG- and
PS-liposomes. Furthermore, depletion of C1q significantly reduced up-
take of PG-liposomes. Therefore, another explanation for the higher
potency of DSPG-liposomes could be that they attract C1q from the
circulation more efficiently than DPPS-liposomes. Since C1q cannot
bind to free PS or PG [70], the density and repetitiveness of anionic
head groups on liposomes may be an important parameter that affects
C1q binding [81]. The molar ratios of the lipids used in this study were
identical, so this would not affect binding of C1q. It has also been
suggested that the electrostatic charge of the liposomes is an important
parameter for binding [80,82], or that the chemical structure of the
lipids is crucial [83]. In this work, the zeta-potential was the same for
both liposomal formulations, leaving the structure of the phospholipid
Fig. 6. Histological analysis of lesion formation in the aortic valve area of LDLr−/− mice. LDLr−/− mice on a WTD were administered either with PBS, 10 nmol free
p3500 or 10 nmol p3500 encapsulated in DSPG-liposomes via i.p. injection every 3weeks for 10weeks on a WTD. (A) Lesion area as determined by Oil-Red-O
staining. (B) Representative images of sections of the aortic valve area in a mouse receiving PBS or DSPG/p3500-liposomes. Stainings shown are Oil-Red-O (ORO) and
hematoxylin, monocyte/macrophage marker (MOMA2), and Sirius Red. In the Sirius Red staining, Type I collagen fibers are stained red, while Type III collagen fibers
appear green. (C) The weight of mice at sacrifice. (D) Serum cholesterol levels of mice at sacrifice. (E) Percentage of macrophage area relative to total lesion area as
determined by MOMA2 staining. (F) Percentage of collagen area relative to total lesion area as determined by Sirius Red staining. Graphs show mean ± SD (n=9),
*p < .05, **p < .01 determined by one-way ANOVA and Bonferroni's multiple comparisons tests. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
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headgroup as the only differing factor.
Since there was a clear role for C1q in the uptake of the liposomes,
we hypothesized that this may also influence Treg skewing. While we
did observe that the addition of C1q increases Treg responses compared
to serum-free conditions, this was not significant. Similarly, Clarke et al.
showed that, while C1q tolerizes macrophages (increased PD-L1 and
PD-L2, decreased CD40) and DCs (increased PD-L2 and decreased
CD86), there was only a trend towards higher Treg responses [84]. This
suggests that C1q is partially responsible for the Treg induction of both
DSPG- and DPPS-liposomes, but the protein corona likely contains more
components that help to induce Tregs.
Finally, we tested whether our most tolerogenic formulation was
able to prevent disease progression in atherosclerosis. We immunized
atherosclerotic mice with 10 nmol of our newly identified ApoB100-
derived peptide (p3500), either free or encapsulated inside DSPG-li-
posomes. We observed a highly significant decrease in atherosclerotic
lesion size of 50% only in the group that was immunized with the
p3500 liposomes. Interestingly a previous study where ApoE−/− mice
received a similar MHC-II restricted ApoB100-derived peptide
(ApoB1003501–3516) in complete Freund's adjuvant (CFA), and four
booster injections in incomplete Freund's adjuvant (IFA) showed a
comparable reduction in aortic plaque formation of 60% [23]. In ad-
dition, there were no changes in Treg populations upon this treatment
[23], which is similar to our findings. In a more recent paper by the
same group using a novel ApoB100-derived peptide and custom tetra-
mers, antigen-specific Tregs were found [28]. This is in spite of that fact
that CFA and IFA are not designed for tolerogenic responses; in fact,
they generally elicit strong Th1 and Th2 responses [85]. This may ex-
plain why this previous study required a 3-fold higher peptide dose to
induce the same atheroprotective effect we report. Moreover, because
of their high toxicity, use of CFA or IFA in humans is strongly dis-
couraged [85]. Unfortunately, we were unable to measure p3500-spe-
cific Tregs in this atherosclerosis study, due to lack of specific tetra-
mers, however we did exclude the possibility that that protective effect
was mediated by empty DSPG liposomes.
We further observed a significant decrease in serum cholesterol le-
vels in mice receiving DSPG/p3500 treatment. It has been shown that
depletion of Tregs increased cholesterol levels in LDLr−/− mice [86],
while in vivo Treg expansion in LDLr−/− mice reduced cholesterol le-
vels [87], so this decrease in cholesterol levels could be caused by an
increase in the number of antigen-specific Tregs. Finally, an increase in
collagen content in the lesions of mice that received liposomes in-
dicated more stable lesions. In accordance with this, treatment of
ApoE−/− mice with Tregs decreased lesion size and lesion macrophage
content while increasing lesion collagen content [88].
Collectively, these data show that we were able to induce high
numbers of antigen-specific CD25+FOXP3+CD4+ Tregs in mice after a
single injection of DSPG-containing liposomes. Furthermore, our pep-
tidomics strategy was able to identify a novel ApoB100-derived peptide
to be used for vaccination against atherosclerosis. We show that DSPG-
liposomes, only when loaded with the ApoB100-derived peptide, sig-
nificantly reduced lesion size, lowered serum cholesterol levels, and
stabilized lesions in a murine model of atherosclerosis. Therefore,
DSPG-liposomes can be a useful delivery vehicle for the induction of
antigen-specific Tregs for the treatment of atherosclerosis and other
autoimmune diseases.
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